{
  "id": 8256157,
  "title": "Ultragenyx prices Sanfilippo gene therapy at $4M; Bristol Myers shelves Orum drug",
  "url": "https://urgent.news/2026/09/18/ultragenyx-prices-sanfilippo-gene-therapy-at-4m-bristol-myers-shelves",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-18T14:24:00.000Z",
  "source": {
    "name": "BioPharma Dive",
    "slug": "biopharma-dive",
    "url": "https://www.biopharmadive.com/news/ultragenyx-fayuvi-orum-bristol-lunsumio-longeveron-rocket-danon/830512/"
  },
  "original_language": "en",
  "account": null,
  "summary": "Ultragenyx has received approval for a gene therapy to treat Sanfilippo syndrome type A, a rare disease. The therapy is called Fayuvi. According to BioPharma Dive, this is Ultragenyx's second gene therapy approval since August.\n\nThe price of the therapy has been set at $4 million, as reported by an unnamed source, though Ultragenyx did not immediately release this information to STAT News. The approval has been welcomed by patient advocates, who see it as a significant step forward in treating the disease.\n\nBristol Myers Squibb has discontinued development of a certain drug, BMS-986497/ORM-6151, as reported by Endpoints News. No further details were provided on the reasons for this decision.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 3,
    "also_reported_by": [
      {
        "outlet": "Endpoints News",
        "title": "FDA approves Ultragenyx's gene therapy for Sanfilippo syndrome type A",
        "url": "https://urgent.news/2026/09/17/fda-approves-ultragenyxs-gene-therapy-for-sanfilippo-syndrome-type-a",
        "published": "2026-09-17T19:04:26.000Z"
      },
      {
        "outlet": "STAT News",
        "title": "STAT+: FDA approves a new gene therapy for Sanfilippo syndrome, an ultra-rare disease",
        "url": "https://urgent.news/2026/09/17/stat-fda-approves-a-new-gene-therapy-for-sanfilippo-syndrome-an-ultra",
        "published": "2026-09-17T19:55:46.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}